🇮🇳

India Market Intelligence

· daily

BSE Sensex 30 Stocks Regulatory Filings — May 20, 2026

The 17 filings from BSE SENSEX 30 constituents reveal a mixed picture: Bharti Airtel's record revenue and rising dividend signal strength, but its sluggish ARPU growth and a minor regulatory penalty highlight sector headwinds. Reliance Industries' routine corporate actions (striking off an associate, liquidating a subsidiary) are immaterial, but its partnership with Major League Baseball signals a strategic push into sports and media. HCL Infosystems' deepening losses and eroded net worth are a stark contrast, underscoring a severe financial distress. The banking sector shows active investor engagement, with Axis Bank, ICICI Bank, Kotak Mahindra Bank, and SBI all holding meetings, but no new price-sensitive information was shared. Bajaj Finance's large NCD issuance at 8.08% reflects strong credit demand and a long-term funding strategy. Overall, the period-over-period data highlights Bharti Airtel's revenue growth (lifetime high) and HCL Infosystems' revenue collapse (-74.3% YoY), while insider activity and forward-looking guidance are largely absent, limiting actionable signals.

1 high priority 16 medium 17 total filings
· daily

India MCA Insolvency Liquidation Filings — May 20, 2026

The India MCA Insolvency & Restructuring Monitor for May 20, 2026, reveals a mixed landscape with procedural delays and structural restructuring dominating the three filings. Tricom Fruit Products Ltd remains in active insolvency, with a CoC meeting scheduled for May 26, 2026, to approve audited results, but no financial data or period comparisons are available, limiting trend analysis. Strides Pharma Science Limited secured NCLT approval for a demerger of its Life Sciences and Digital Innovation businesses from Arco Lab into Pivot Path, with a retrospective appointed date of April 10, 2025, signaling a strategic simplification. Vikas WSP Ltd. faces a procedural setback as its NCLT hearing on May 18, 2026, was adjourned to June 2, 2026, due to bench unavailability, extending its CIRP timeline since February 2022. No insider trading activity, capital allocation changes, or forward-looking guidance were reported across any filing, indicating a lack of management conviction signals. The absence of period-over-period financial comparisons and operational metrics across all three filings limits quantitative trend analysis, but the Strides demerger presents a potential catalyst for unlocking value. Overall, the monitor highlights a cautious environment where resolution timelines are stretched, but strategic restructuring moves offer selective opportunities.

3 high priority 3 total filings
· daily

India Corporate Governance MCA ROC Filings — May 20, 2026

The May 20, 2026, batch of 50 MCA corporate governance filings reveals a market dominated by routine board meeting notices for Q4/FY26 results, masking significant underlying divergence. While several companies like Lactose (India) and Control Print posted strong double-digit revenue growth, a worrying cluster of micro-cap and small-cap firms—including Welcast Steels, Ramgopal Polytex, and Jolly Plastic Industries—reported severe financial distress, with losses widening and operations ceasing. Capital allocation is a key theme, with multiple companies (Samvardhana Motherson, Grasim, Carysil) recommending or declaring dividends, signaling confidence, while distressed firms like Welcast and Jolly Plastic have suspended payouts entirely. Insider trading windows are universally closed, providing no actionable insider sentiment, but forward-looking statements reveal significant capital expenditure plans at IOL Chemicals (₹22.75 Cr) and a massive ₹250 Cr fundraise proposal at Borosil Scientific. The most critical development is the permanent plant closure at Welcast Steels, a material event with severe financial implications. Portfolio-level patterns show a clear bifurcation: established players are returning cash and investing in growth, while a subset of smaller entities is facing existential challenges, creating both risks and potential deep-value opportunities.

50 medium 50 total filings
· daily

India Stock Market Daily Regulatory Digest — May 20, 2026

The May 20, 2026, filing batch reveals a market dominated by end-of-fiscal-year reporting, with 50+ companies announcing board meetings for Q4 and FY26 results. Key themes include a strong focus on capital returns, with several companies like Samvardhana Motherson, Grasim, Eris Lifesciences, and Aptech declaring or recommending dividends, signaling confidence in cash flows. However, the data also shows significant divergence in performance, with standout growth in pharma (Lactose India, IOL Chemicals) and auto ancillaries (Samvardhana Motherson), contrasted by sharp deterioration in small-cap industrials (Jolly Plastic, Ramgopal Polytex) and a major related-party transaction at IRB Infrastructure. Insider trading activity is notably absent from the filings, but forward-looking statements point to capacity expansions at IOL Chemicals and a large debt raise at Samvardhana Motherson. The most critical development is the IRB Infrastructure deal, a ₹23,000 crore related-party arrangement that will require close monitoring for shareholder approval and execution. Overall, the digest points to a market rewarding scale and execution in large-caps while punishing weak balance sheets in smaller entities.

2 high priority 48 medium 50 total filings
· daily

India Debt Bond Securities SEBI Regulatory Filings — May 20, 2026

Eight debt-market filings on 20-May-2026 show active private-placement NCD activity across NBFCs/financial services and one large corporate’s board approval for a sizeable unsecured NCD program. Issuances are concentrated in secured debentures (MAS, Unifinz, Mangal, Richfield) with asset cover typically 1.1x–1.2x; coupon spreads vary widely (8.08% – 13%) reflecting credit quality and tenors. Period comparisons (where available) show a tilt toward longer-tenor, institutional-backed paper (MAS 5-year to FMO; Bajaj 10-year institutional-sized deal) and continued use of private-placement channels rather than public listings (5/8 are private placements; 3/8 listed or in-principle listing). The most material items: Samvardhana Motherson’s board approval for up to INR 5,000 Cr of unsecured NCDs (potentially dilutive to unsecured-credit pool) and Bajaj Finance’s large INR 1,025 Cr 10-year issue with a 3-year put option (liability-duration extension with embedded optionality). Portfolio-level patterns: durable demand from institutional lenders for secured paper, yield segmentation by credit rating (CARE AA- vs BBB-), and continued reliance on NCDs/CP for working-capital and long-term funding. Market implication: credit supply is active with differentiated pricing by credit quality; watch unsecured large-cap NCD program (Samvardhana) for pricing and placement dynamics that could reprice corporate long-end unsecured curve.

8 medium 8 total filings
· daily

India Healthcare Pharma Policy Regulatory Filings — May 20, 2026

All 8 filings relate to Apollo Hospitals Enterprise, revealing a major strategic pivot during FY2025-26. The company posted solid standalone revenue growth of 13.7% YoY to ₹93,262 Mn and PAT growth of 15.1% YoY, but Q4 FY2026 showed a clear deceleration with sequential revenue growth of only 3.2% and EBITDA flat QoQ, raising concerns about near-term momentum. The most critical development is the restructuring of its Mother & Child and Fertility verticals via a combination with Cloudnine in a deal valuing those assets at ₹1,550 Cr (subsequently confirmed with an enterprise value of ~₹15,500 Mn for the divested entities), where Apollo will receive cash plus a 9.9% stake in the combined entity. This, along with the merger of Apollo Hospitals North Ltd, signals a balance-sheet optimization strategy. However, a correction filing reveals that the two divested subsidiaries have negative networth (ASHPL: ₹-153.84 Cr, AFCPL: ₹-38.33 Cr), which may indicate a distressed exit. The Digital Health segment continues to bleed cash (₹16 Cr loss in Q4), offsetting strong performance in Healthcare Services (occupancy 68%, ARPIP up 9% YoY). The reappointment of Dr. Prathap C Reddy as Executive Chairman for two more years provides leadership stability. A final dividend of ₹10/share (200%) has been recommended, reflecting continued shareholder returns.

5 high priority 3 medium 8 total filings
· daily

India SEBI Regulatory Enforcement Actions — May 20, 2026

The 18 filings in this stream paint a mixed picture of the Indian regulatory and corporate landscape, dominated by a handful of high-impact events. The most significant theme is **Sammaan Capital's strategic transformation**: despite reporting a massive ₹8,101-crore net loss (driven by a ₹6,499-crore exceptional charge and portfolio repositioning), the company secured an ₹8,850-crore equity infusion from IHC and received a full sweep of credit rating upgrades (CRISIL, CARE, ICRA) to 'AA+/Stable' within 50 days, signaling a successful balance sheet cleanup. **Apollo Hospitals** shows robust full-year growth (+13.7% revenue, +15.1% PAT) but a clear sequential slowdown in Q4 (+3.2% revenue QoQ), coupled with strategic divestments of its fertility and specialty hospital chains to Kids Clinic India for ₹15,500 crore EV—a move to unlock value. **Bharti Airtel** reported a lifetime-high consolidated revenue of ₹2.11 lakh crore, but its India mobile ARPU growth was disappointing (+₹3 to ₹257), with management calling it unsatisfactory due to international roaming headwinds. **Fine Organic Industries** delivered a mixed result with Q4 PAT surging 21% YoY but full-year EBITDA declining 5.8% due to raw material cost pressures, while announcing a strategic acquisition in Malaysia. Several specialty chemical companies (DCM Shriram Fine Chemicals, Gandhar Oil, Camlin Fine Sciences) are reporting financial results for the fiscal year, with DCM showing a sharp net profit decline (from ₹1,845 Lakh to ₹429 Lakh). The period-comparison data reveals a sector-wide theme of **cost inflation and margin compression** across healthcare and chemicals, while the **capital allocation pattern** favors dividends (Apollo, DCM, Bharti, NGL Fine-Chem) and debt-raising (Sammaan up to ₹10,000 crore) over buybacks.

18 high priority 18 total filings
· daily

BSE Metal Sector Regulatory Filings — May 20, 2026

The BSE METAL sector shows a bifurcated picture on May 20, 2026: **SAIL** delivers a standout operational and earnings beat with record sales volumes, robust PAT growth (+51% YoY), and aggressive deleveraging, while the **JSW Steel** ecosystem presents a mixed narrative. A notable insider risk emerges as the JSW Group promoter entity (JSW Energy) sold a significant 1.02% stake in JSW Steel worth approximately INR 1,460 crore, reducing promoter holding to 44.29%; this event overshadows JSW Steel's procedural analyst meet transcript filing which contains no new financial guidance. The key period-over-period theme is **volume-led growth** in the sector, but this is being challenged by sharp input cost inflation (coking coal up 15% QoQ in a single month). While SAIL demonstrates strong operational execution with improving NSR trends of INR 4,000 per ton in early FY27, the coking coal surge threatens margin recovery across the sector. SAIL's forward-looking guidance for 22mt sales volume in FY27 provides a major catalyst, contrasting with no fresh outlook from JSW Steel. The combination of SAIL's bullish signals and JSW's promoter divestment creates a complex sector dynamic where operating leverage may be offset by margin compression fears.

3 medium 3 total filings
· daily

BSE Auto Sector Regulatory Filings — May 20, 2026

The May 20, 2026, batch of 15 BSE AUTO filings reveals a sector in a robust growth phase, with aggregate automotive production volumes surging 17% YoY in Q4 FY26, but with significant divergence in profitability and shareholder returns. Samvardhana Motherson International and Bosch Limited both reported strong top-line growth (consolidated revenues of Rs 92,911 Cr for Motherson and Rs 20,034 Cr for Bosch in FY26), yet their dividend policies tell opposite stories: Motherson increased its payout by 5.3% YoY, while Bosch slashed its final dividend by 47.3% YoY, signaling a strategic shift toward reinvestment. A critical mixed signal emerges from Motherson's group performance, where 59 unaudited subsidiaries posted a net loss of Rs 127 Cr, tempering the headline growth. The most transformative corporate action is Ashok Leyland's subsidiary merger (Hinduja Leyland Finance into NDL Ventures), which has cleared a major SEBI/BSE hurdle, unlocking potential value. Insider activity is absent across all filings, but forward-looking events (AGMs, investor conferences, record dates) create a clear catalyst calendar for the next 90 days. The overarching theme is 'growth with caution,' as companies navigate margin pressures and capital allocation trade-offs in a high-volume environment.

15 medium 15 total filings
· daily

BSE FMCG Sector Regulatory Filings — May 20, 2026

The six filings from S&P BSE FMCG constituents on May 20, 2026, reveal a sector in a holding pattern, dominated by procedural corporate governance updates and investor conference participations rather than material financial disclosures. No period-over-period comparisons (YoY/QoQ), forward-looking guidance, insider transactions, or capital allocation changes were reported in any of the filings, resulting in a neutral sentiment across the board. Key themes include a cluster of board meetings scheduled between May 25-28, 2026, for approving FY2025-26 audited results, with Emami Paper Mills notably including a dividend recommendation on its agenda. The alcoholic beverages sub-sector is active in investor outreach, with both Radico Khaitan and United Spirits participating in multiple domestic and international conferences, signaling a proactive investor relations push. However, the complete absence of quantitative financial data, insider activity, or strategic guidance in these filings limits actionable insights, making the upcoming board meetings the primary catalyst for the sector in the near term.

6 medium 6 total filings
· daily

BSE IT Technology Sector Regulatory Filings — May 20, 2026

The five filings from S&P BSE IT constituents reveal a stark divergence between large-cap IT services firms and smaller, distressed entities. While Wipro and Persistent Systems are engaged in routine corporate actions (RSU grants and investor meetings) with neutral sentiment, HCL Infosystems reported a catastrophic 74.3% YoY revenue decline and a widening net loss, with a fully eroded net worth and a negative equity base of ₹29,927 Lakh. This contrasts sharply with the sector's typical growth narrative. A key period-over-period trend is the severe deterioration at HCL Infosystems, where losses deepened by 53% YoY, and current liabilities exceed current assets by ₹45,510 Lakh, signaling a solvency crisis. Meanwhile, Mphasis saw a material 30.55% promoter share pledge, indicating significant debt financing by the promoter BCP Topco IX Pte. Ltd., which introduces leverage risk. The most critical development is the HCL Infosystems' going-concern risk, despite a favorable arbitration award of ₹10,281 Lakh against UIDAI, which is under challenge and provides no immediate liquidity. The portfolio-level pattern is one of bifurcation: established players focus on long-term incentives and investor relations, while weaker entities face existential financial stress and promoter-level debt encumbrance.

5 medium 5 total filings
· daily

BSE Bankex Banking Sector Regulatory Filings — May 20, 2026

The six filings from S&P BSE BANKEX constituents for May 20, 2026, are predominantly routine regulatory disclosures with neutral sentiment and low materiality, indicating a period of operational stability rather than transformative events. The most notable pattern is a surge in global investor engagement, with three major banks (Axis Bank, SBI, and ICICI Bank) conducting or scheduling investor meetings in Hong Kong, Boston, and via the UBS Asian Investment Conference, respectively, signaling aggressive international outreach to attract foreign institutional investment. Kotak Mahindra Bank is also hosting domestic investor meetings in Mumbai, reinforcing a sector-wide focus on investor relations. A single corporate action from Bank of Baroda pertains to a routine dividend tax notification, while Yes Bank reported a senior-level resignation in its transaction banking division, a minor but notable personnel change. No period-over-period financial trends, insider trading activity, forward-looking guidance, or capital allocation changes were disclosed in any of the filings, limiting the depth of quantitative synthesis. The overarching theme is one of proactive stakeholder communication and global positioning rather than material business shifts, with the upcoming investor meets on May 26-29, 2026, serving as key near-term catalysts for stock price movement and sentiment.

6 medium 6 total filings
· daily

BSE Pharma Sector Regulatory Filings — May 20, 2026

The 12 filings from S&P BSE PHARMA constituents reveal a sector dominated by Apollo Hospitals, which accounts for 9 of the 12 filings, showcasing a mixed performance: strong YoY revenue and profit growth (13.7% and 15.1% respectively) but a notable QoQ slowdown in Q4 FY2026, with EBITDA margins compressing sequentially. The most critical development is Apollo's strategic divestment of its Mother & Child and Fertility verticals to Kids Clinic India (Cloudnine) for an enterprise value of ₹15,500 million, creating a combined platform of 55+ centres backed by marquee investors—a move that signals a shift toward asset-light, high-growth partnerships. Insider activity is minimal, with no direct trades reported, but the SPARC acquisition filing by promoter-linked Shanghvi Finance suggests potential confidence in its pipeline. Capital allocation trends show Apollo maintaining a ₹10/share dividend (200% payout) while pursuing a subsidiary merger, indicating a balanced approach to returning cash and streamlining operations. Portfolio-level patterns highlight a divergence between robust annual performance and near-term deceleration, with Apollo's Q4 revenue growth of only 3.2% QoQ and flat EBITDA raising concerns about demand sustainability. The Zydus Lifesciences investment in Torrent Urja 25 (₹12.88 Cr for 22.06% stake) reflects a niche capital allocation move into energy, while Alkem and Mankind's earnings call announcements set the stage for upcoming sector-wide results. Overall, the sector shows resilience but faces margin pressure and a need for catalysts to sustain momentum.

5 high priority 7 medium 12 total filings
· daily

India BSE NSE Trading Suspension Orders — May 20, 2026

The 9 filings reveal a stark divergence between India's healthcare and financial sectors. Apollo Hospitals shows robust 13.7% YoY revenue growth and 15.1% PAT growth, but sequential Q4 data reveals a slowdown with only 3.2% revenue growth and flat EBITDA, signaling potential maturity in its core business. The company is strategically divesting non-core fertility and specialty hospital assets for ₹15,500 million, indicating a portfolio optimization play. In contrast, Sammaan Capital (formerly Indiabulls Housing Finance) is undergoing a radical restructuring, reporting a massive net loss of ₹8,101 crore in Q4 FY26 driven by ₹6,499 crore in exceptional losses and ₹2,958 crore in impairments, reflecting a clean-up of its loan book. However, this is paired with a ₹8,850 crore capital infusion from IHC and a full upgrade cycle by all three domestic rating agencies to 'AA+/Stable', signaling a potential turnaround. Bharti Airtel reported a lifetime high revenue of ~₹2,11,000 Crore for FY2026, but its India mobile ARPU growth was a disappointing ₹3 to ₹257, with management calling it 'unsatisfactory', partly due to the West Asia crisis. The board's approval to acquire an additional 16.3% stake in Airtel Africa via a share swap and a 50% dividend hike to ₹24 per share are key capital allocation signals. Overall, the period comparisons show Apollo's growth deceleration, Sammaan's strategic reset, and Airtel's top-line strength with ARPU concerns.

9 high priority 9 total filings
· daily

India IPO Pipeline SEBI Regulatory Filings — May 20, 2026

The 11 filings reveal a bifurcated market: Apollo Hospitals and Bharti Airtel demonstrate strong operational momentum with double-digit revenue growth (13.7% and lifetime highs, respectively), while Sammaan Capital undergoes a radical restructuring, posting a massive ₹8,101 Cr net loss in Q4 FY26 driven by ₹6,499 Cr in exceptional items and a strategic portfolio repositioning. The IPO pipeline is notably absent of new IPO filings, with the most actionable capital markets activity being Apollo's ₹15,500 Mio divestment of fertility and specialty hospital assets to Kids Clinic India, and U.P. Hotels' impending voluntary delisting from the BSE. A key cross-cutting theme is capital optimization: Apollo is streamlining via a subsidiary merger and asset sale, Sammaan is deleveraging after an ₹8,850 Cr IHC equity infusion, and Jay Bharat Maruti is cutting costs by delisting from the dormant Calcutta Stock Exchange. Insider activity is sparse but significant—Sammaan’s rating upgrades by all three agencies (CRISIL, CARE, ICRA) within 50 days of the IHC infusion signal strong institutional confidence in its turnaround. Forward-looking catalysts include Apollo’s AGM and dividend record date (Aug 14, 2026), U.P. Hotels’ delisting board meeting (May 28, 2026), and Sammaan’s plan to raise up to ₹10,000 Cr via debt, which could accelerate disbursals. Overall, the digest points to a market favoring quality compounders (Apollo, Airtel) over distressed plays, with limited near-term IPO supply.

11 high priority 11 total filings
· daily

India NCLT Insolvency Resolution Filings — May 20, 2026

The 32 filings reveal a stark divergence in corporate health: Sammaan Capital (formerly Indiabulls Housing) is undergoing a massive balance sheet cleanup with a ₹7,145 Cr net loss and exceptional charges of ₹6,499 Cr, yet its new promoter IHC has infused ₹5,652 Cr and credit ratings have been upgraded to AA+ by all three agencies, signaling a high-risk turnaround. Apollo Hospitals shows steady 13.7% revenue growth and 15.1% PAT growth, but Q4 sequential revenue growth slowed to 3.2% and EBITDA was flat, while it divests its maternity/fertility verticals to Cloudnine for ₹1,550 Cr enterprise value. Bharti Airtel reported record revenue of ₹2.11 lakh Cr and EBITDA margin of 51.2%, but ARPU growth was only ₹3 to ₹257, deemed unsatisfactory. Insolvency-related filings (Tricom Fruit Products, Vikas WSP) show procedural delays, while Strides Pharma's NCLT-approved demerger of its life sciences business is a positive restructuring. No insider trading activity was reported in any filing, limiting that angle.

12 high priority 20 medium 32 total filings
· daily

India Sector Consolidation Regulatory Filings — May 20, 2026

The May 20, 2026, filing batch reveals a powerful wave of corporate restructuring and strategic consolidation across Indian sectors, with a distinct focus on renewable energy captive power procurement. A clear pattern emerges of large, cash-rich industrial groups (Grasim, Vodafone Idea, KEI Industries, Zydus Lifesciences, Chemfab Alkalis) investing in minority stakes in renewable energy SPVs to secure cost-effective green power and comply with regulatory mandates. Simultaneously, a significant number of filings involve internal group restructuring through mergers of wholly-owned subsidiaries (Triveni Engineering, Autoline Industries, Lenskart, Apollo Hospitals), aimed at simplifying structures and reducing costs. The M&A landscape is also marked by high-value, complex transactions, including Apollo Hospitals' ₹1,550 crore divestment of fertility/hospital assets and Lenskart's continued consolidation of OWNDAYS. However, the data is heavily skewed by a large number of 'low materiality' regulatory disclosures under SEBI SAST regulations, which provide limited actionable intelligence. The most critical developments for investors are the forward-looking catalysts from the NCLT hearing schedules (Utkarsh SFB, GOCL Corp) and the significant insider buying by Paisalo Digital's promoter group, which contrasts with notable insider selling in Ganesh Benzoplast.

1 high priority 48 medium 49 total filings
· daily

India SEBI Compliance Enforcement Orders — May 20, 2026

The three filings present a bifurcated regulatory landscape. Birlasoft's clean compliance report signals a low-risk governance environment, while Apollo Hospitals' mixed financial results and major corporate actions (divestiture, merger) create both opportunities and execution risks. Key period-over-period trends show Apollo's revenue growing 13.7% YoY but Q4 momentum stalling (3.2% QoQ growth), with EBITDA margins compressing sequentially. The most critical development is Apollo's ₹15,500 million divestment of non-core assets to Kids Clinic India, which could unlock value but also signals a strategic pivot. No portfolio-level insider trading activity was detected, but Apollo's capital allocation (dividend increase, M&A) suggests a focus on shareholder returns and portfolio rationalization. The overall theme is one of regulatory stability (Birlasoft) versus active corporate restructuring (Apollo), with the latter offering higher alpha potential but also greater risk.

1 high priority 2 medium 3 total filings
· daily

India IPO SEBI DRHP Activity Filings — May 20, 2026

The six filings in this India IPO Activity Monitor brief are dominated by corporate restructuring and regulatory compliance actions rather than direct IPO activity, with Reliance Industries disclosing two routine subsidiary wind-downs (BAM DLR Kolkata and Roptonal Limited) that have negligible financial impact (Roptonal contributed only 0.0012% to consolidated net worth). The most material developments are the voluntary delisting actions from U.P. Hotels Ltd. (from BSE, with a board meeting on May 28, 2026) and Jay Bharat Maruti Limited (from CSE, citing zero trading for years), signaling a trend of companies exiting less liquid exchanges to reduce compliance costs. ICICI Bank's investor meet at the UBS Asian Investment Conference (May 26-27) and Bharti Airtel's minor regulatory penalty of ₹2,09,000 for subscriber verification norms round out the filingscars. Period-over-period trends are limited as most filings lack financial data, but the delisting actions highlight a portfolio-level pattern of companies prioritizing cost efficiency and liquidity concentration on major exchanges (NSE/BSE). The most critical development is U.P. Hotels' delisting from BSE, which carries a materiality of 9/10 and could impact shareholder liquidity, while Jay Bharat Maruti's CSE delisting is a lower-risk move given the exchange's inactivity. Overall, the brief suggests a market environment where companies are streamlining corporate structures and reducing administrative burdens, with no new IPO filings or listings to report.

2 high priority 4 medium 6 total filings
· daily

India Monetary Policy RBI MPC Decisions — May 20, 2026

The 12 filings reveal a complex macro backdrop where the RBI is actively managing liquidity through short-term operations (VRR, USD/INR swaps) without altering policy rates, signaling a neutral stance with a deficit bias. Corporate earnings show a stark divergence: Apollo Hospitals and Bharti Airtel delivered robust double-digit revenue and profit growth (13-18% YoY), but Sammaan Capital reported a massive ₹8,101 crore net loss driven by strategic portfolio clean-up, offset by a complete credit rating upgrade cycle to AA+/Stable following IHC's equity infusion. Insider activity is absent across filings, but capital allocation patterns are strong—Apollo and Airtel raised dividends (200% payout and 50% YoY increase respectively), while Sammaan's board approved ₹10,000 crore in debt raising. The key portfolio-level theme is a 'cleansing vs. growth' dichotomy: Sammaan is taking one-time hits for future strength, while Apollo and Airtel are monetizing non-core assets (Apollo's fertility chain sale for ₹15,500 Mn) to focus on core operations. The RBI's liquidity injections suggest systemic tightness, which may pressure NBFCs like Sammaan in the near term but benefit well-capitalized players.

12 high priority 12 total filings